Summary
Boston Scientific Corporation (BSX) reported its third-quarter and nine-month results for the period ending September 30, 2006. The company's financial performance was significantly impacted by the recent acquisition of Guidant Corporation, which closed on April 21, 2006. This major acquisition led to a substantial increase in net sales, driven by the integration of Guidant's Cardiac Rhythm Management (CRM) and Cardiac Surgery divisions. However, the acquisition also resulted in a significant net loss for the nine-month period, largely due to substantial purchase accounting adjustments, including a large amount attributed to purchased research and development and the step-up in value of acquired inventory. The company also incurred considerable merger-related costs and integration expenses. Despite these charges, management highlighted sales growth in key segments and is focused on integrating Guidant, addressing FDA warning letters for both legacy BSX and acquired Guidant facilities, and navigating competitive market dynamics, particularly in the coronary stent and CRM sectors.
Key Highlights
- 1Net sales increased by 34% to $2,026 million in Q3 2006 compared to Q3 2005, primarily due to the inclusion of Guidant's CRM and Cardiac Surgery divisions' sales.
- 2The company reported a net loss of $3,854 million for the nine months ended September 30, 2006, a significant change from a net income of $294 million in the prior year, largely due to acquisition-related expenses and purchase accounting adjustments.
- 3Gross profit margin decreased to 68.9% in Q3 2006 from 77.3% in Q3 2005, negatively impacted by acquisition costs, including $94 million for the step-up value of acquired Guidant inventory sold.
- 4Selling, General, and Administrative (SG&A) expenses increased by 62% to $719 million in Q3 2006 compared to Q3 2005, driven by $235 million in expenditures associated with Guidant.
- 5Research and Development (R&D) expenses increased by 50% to $272 million in Q3 2006 compared to Q3 2005, reflecting $99 million in expenditures associated with Guidant.
- 6Amortization expense increased significantly to $153 million in Q3 2006 from $47 million in Q3 2005, largely due to $120 million in amortization of intangible assets acquired in the Guidant acquisition.
- 7Outstanding debt increased substantially to $8,898 million at September 30, 2006, from $2,020 million at December 31, 2005, primarily to finance the cash portion of the Guidant acquisition.